Resource Summary Report

Generated by RRID on Sep 2, 2026

SU-DHL-10

RRID:CVCL_1889
Type: Cell Line

Proper Citation

RRID:CVCL_1889

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1889

Proper Citation: RRID:CVCL_1889

Description: Cell line SU-DHL-10 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: PMID:83902, PMID:177185, PMID:214220, PMID:371794, PMID:1465024, PMID:3881165, PMID:8547074, PMID:9738977, PMID:9787181, PMID:19278952, PMID:19358282, PMID:20054396, PMID:20215515, PMID:20628145, PMID:22460905, PMID:23257783, PMID:25355872, PMID:25485619, PMID:25877200, PMID:26589293, PMID:26727417, PMID:27397505, PMID:28196595, PMID:29416618, PMID:29666304, PMID:30285677, PMID:30629668, PMID:30894373, PMID:30971826, PMID:31068700, PMID:35839778

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SU-DHL-10

Synonyms: Su-DHL-10, SUDHL10, Sudhl10, SUDHL-10, SuDHL 10, Stanford University-Diffuse Histiocytic Lymphoma-10, DHL10

Cross References: CLO:CLO_0037059, EFO:EFO_0002354, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610,

ATCC:CRL-2963, BioGRID_ORCS_Cell_line:1024, BioSample:SAMN03471872, BioSample:SAMN10988471, cancercelllines:CVCL_1889, CCTCC:GDC0217, Cell_Model_Passport:SIDM00389, ChEMBL-Cells:CHEMBL4483178, ChEMBL-Targets:CHEMBL4483268, Cosmic:850207, Cosmic:1067460, Cosmic:1079257, Cosmic:1517644, Cosmic:1541914, Cosmic:1636685, Cosmic:2276343, Cosmic:2361377, Cosmic-CLP:1331033, DepMap:ACH-000271, DSMZ:ACC-576, DSMZCellDive:ACC-576, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1331033, GEO:GSM380143, GEO:GSM552468, GEO:GSM887651, GEO:GSM888743, GEO:GSM1035312, GEO:GSM1059808, GEO:GSM1374904, GEO:GSM1670483, IARC_TP53:28255, IGRhCellID:SUDHL10, LiGeA:CCLE_214, LINCS_LDP:LCL-1134, PharmacoDB:SUDHL10_1500_2019, PRIDE:PXD030304, Progenetix:CVCL_1889, PubChem_Cell_line:CVCL_1889, Wikidata:Q54970706

ID: CVCL_1889

Record Creation Time: 20220427T221611+0000

Record Last Update: 20260830T000035+0000

Ratings and Alerts

No rating or validation information has been found for SU-DHL-10.

No alerts have been found for SU-DHL-10.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. Cell reports. Medicine, 7(3), 102644.

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Rossi A, et al. (2025) Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma. iScience, 28(5), 112333.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood cancer discovery, 6(6), 580.

Manara P, et al. (2025) Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy.

Cancer research.

Prinz LF, et al. (2024) An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL. Cell reports. Medicine, 5(2), 101421.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. Leukemia, 38(10), 2210.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. Blood cancer discovery, 5(6), 417.

Schwarzer A, et al. (2023) Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1. Molecular cancer therapeutics, 22(11), 1290.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Roberto MP, et al. (2021) Mutations in the transcription factor FOXO1 mimic positive selection signals to promote germinal center B cell expansion and lymphomagenesis. Immunity, 54(8), 1807.

Mukherjee R, et al. (2021) Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. Molecular cell, 81(4), 708.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. Cell reports. Medicine, 2(7), 100350.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. Immunity, 54(1), 116.

Park S, et al. (2020) Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in EZH2 Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma. Cancers, 12(9).

Qiu Z, et al. (2020) MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. Cell chemical biology, 27(5), 538.